Evidence map›Paper›PMID 41629764›Full record

ReviewJournal of the National Cancer Institute2026

Salvage of locoregionally recurrent head and neck cancer: an NRG oncology working group review.

Matthew C Ward, Jung Julie Kang, Nabil F Saba, Shauna R Campbell, Neal S Akhave, Steven S Chang, Sharon A Spencer, Anna Spreafico, Glenn J Hanna, Sue S Yom and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Matthew C WardDepartment of Radiation Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, United States.ORCID 0000-0002-8423-890X
Jung Julie KangDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, United States.ORCID 0000-0001-9773-5481
Nabil F SabaDepartment of Hematology and Medical Oncology, The Winship Cancer Institute, Emory University, Atlanta, GA, United States.ORCID 0000-0003-4972-1477
Shauna R CampbellDepartment of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States.ORCID 0000-0002-4486-0294
Neal S AkhaveDepartment of Thoracic-Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer, Houston, TX, United States.ORCID 0000-0002-1291-0218
Steven S ChangDepartment of Otolaryngology Head and Neck Surgery, Henry Ford Health, Detroit, MI, United States.ORCID 0000-0002-8645-1392
Sharon A SpencerDepartment of Radiation Oncology, University of Alabama Birmingham, Birmingham, AL, United States.
Anna SpreaficoDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-3034-3042
Glenn J HannaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-9969-2523
Sue S YomDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, United States.ORCID 0000-0002-0779-7476
Dwight E HeronDepartment of Radiation Oncology, Bon Secours Mercy Health System, Youngstown, OH, United States.ORCID 0000-0001-6282-1806

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
National Cancer Institute of the National Institutes of Health U10CA180868NCI NIH HHS U10 CA180868
6 · The paper itself

Abstract

Despite decades of progress in the treatment of head and neck cancer, recurrence and second primary cancers continue to occur. The management of nonmetastatic, locoregionally recurrent or second primary cancers is a complex multidisciplinary challenge that often occurs without guidance from robust clinical trials. In 2023, the NRG Oncology cooperative group created the Recurrent and Metastatic Working Group with the express directive to investigate how resources could optimally address the key questions for the recurrent and metastatic populations. Here, we present our view of the state of the science and present considerations for future investigations.

Indexed as

Head and Neck NeoplasmsNeoplasm Recurrence, LocalNeoplasms, Second PrimarySalvage TherapyHumans

Identifiers

PMID41629764
PMCPMC12947746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.